Are Traders Bullish On XOMA Corp (NASDAQ:XOMA)?

Posted by Lynn Eisler October 2, 2013 0 Comment 1276 views

There is lot of trading activity which is happening in XOMA Corp (NASDAQ:XOMA) in Option Segment. 3000 Contracts were rolled forward from the month of 5th October’13 to 5th November’13. Traders have been hoping for positive news on several potential drugs which are there in pipeline. $5 Call Option and $5 Put Option is having highest amount of Open Interest with long positions being build up.

Tuesday’s trading

In Tuesday’s trading, XOMA Corp (NASDAQ:XOMA) rose 14.92%. The shares opened at a price of $4.50, climbed to an intraday high of $5.20 and dipped to a close of $5.16. Approximately 2.76 million shares were traded on Tuesday while an average volume of 1.01 million shares were traded over a 30 day period. The 52-week low of the company’s shares is $2.37 and its 52-week high is $5.53. The company has a market capitalization of $118.79 million.

About the company

XOMA Corp (NASDAQ:XOMA) is involved in discovering and developing antibody-based therapeutics. Gevokizumab is the company’s lead drug candidate. This is a humanized monoclonal-allosteric modulating-antibody that is designed to inhibit pro-inflammatory cytokine-interleukin-1 beta. Its preclinical-pipeline includes various classes of antibodies that either activate or sensitize the insulin-receptor in vivo, called XMet. They represent potential and new therapeutic-approaches for treating diabetes and various other diseases that also have insulin-involvement.

On 17 January 2012, XOMA Corp (NASDAQ:XOMA) announced that it had bought the U.S rights from Servier to the portfolio of its antihypertensive products.  This particular portfolio includes ACEON. This is a marketed angiotensin-converting enzyme or (ACE) inhibitor, and 3 different fixed-dose combination (FDC) products where a kind of perindopril (perindopril arginine) is used in combination with an different active ingredient

About Lynn Eisler

Lynn Eisler is a national news reporter focusing on economic issues, data analysis and the financial health of state and local governments. Lynn has been honored with the H.L. Mencken Award for Investigative Reporting, the Champion of Justice Award for reporting on the drug war, and the John Hancock Award for business reporting. Lynn was also a Knight Medical School Fellow at the University of Michigan.

View all post by Lynn Eisler Visit author's website

Write Your Comment